Clinical Trial Results:
A Phase 3 open-label study of Infacort® in neonates, infants and children less than 6 years of age with adrenal insufficiency.
Summary
|
|
EudraCT number |
2014-002265-30 |
Trial protocol |
DE |
Global end of trial date |
20 May 2016
|
Results information
|
|
Results version number |
v1(current) |
This version publication date |
22 Dec 2016
|
First version publication date |
22 Dec 2016
|
Other versions |
Trial Information
Subject Disposition
Baseline Characteristics
End Points
Adverse Events
More Information
Subject Disposition
Baseline Characteristics
End Points
Adverse Events
More Information
|
|||
Trial identification
|
|||
Sponsor protocol code |
Infacort003
|
||
Additional study identifiers
|
|||
ISRCTN number |
- | ||
US NCT number |
- | ||
WHO universal trial number (UTN) |
- | ||
Sponsors
|
|||
Sponsor organisation name |
Diurnal Limited
|
||
Sponsor organisation address |
Cardiff Medicentre, Heath Park, Cardiff, United Kingdom, CF14 4UJ
|
||
Public contact |
David English, Diurnal Limited, 44 2920682069, davidenglish@diurnal.co.uk
|
||
Scientific contact |
David English, Diurnal Limited, 44 2920682069, davidenglish@diurnal.co.uk
|
||
Paediatric regulatory details
|
|||
Is trial part of an agreed paediatric investigation plan (PIP) |
Yes
|
||
EMA paediatric investigation plan number(s) |
EMEA-001283-PIP01-12 | ||
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial? |
No
|
||
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial? |
No
|
||
Results analysis stage
|
|||
Analysis stage |
Final
|
||
Date of interim/final analysis |
05 Oct 2016
|
||
Is this the analysis of the primary completion data? |
Yes
|
||
Primary completion date |
20 May 2016
|
||
Global end of trial reached? |
Yes
|
||
Global end of trial date |
20 May 2016
|
||
Was the trial ended prematurely? |
No
|
||
General information about the trial
|
|||
Main objective of the trial |
To demonstrate significant absorption of hydrocortisone from the Infacort® preparation.
|
||
Protection of trial subjects |
Before enrolment every subject (both parents/carers) received full oral and written information about the nature, purpose, expected advantages and possible risks of the trial. The parents/carers agreed to participation in the trial by signing the informed consent form. They were given an opportunity to enquire about details of the study. After a sufficient period of time (at least 1 night) for the individual’s consideration and decision, comprehension and consent were documented on the consent form by the dated signature of both the subject’s parents/carers and the Investigator/treating doctor. Children aged 3 to 6 years were informed about their involvement in the study in the presence of their parents/carers. Both the subject information and the subject consent forms were prepared in duplicate. One of each form was kept by the Investigator, and the other was given to the subject or their parents/carers.
All information sheets and consent forms were provided in German, the country in which the study was conducted.
Since only one dose of the subject’s usual IRHC was replaced with Infacort® and the dose used was the same as the IRHC dose the subject was receiving before the study, the risk of study participation was considered to be minimal. Children usually take their medication every 8 hours so the maximum sampling period up to 8 hours after the Infacort® dose would not delay the subject’s usual dosing pattern. Further risk minimisation was provided by treating older children (who are more robust and less prone to hypoglycaemia due to steroid deficiency) before the younger children, and proceeding to the younger children only after a satisfactory assessment of all safety data by the IDMC.
|
||
Background therapy |
- | ||
Evidence for comparator |
- | ||
Actual start date of recruitment |
11 Mar 2015
|
||
Long term follow-up planned |
Yes
|
||
Long term follow-up rationale |
Safety, Efficacy, Ethical reason, Regulatory reason, Scientific research | ||
Long term follow-up duration |
30 Months | ||
Independent data monitoring committee (IDMC) involvement? |
Yes
|
||
Population of trial subjects
|
|||
Number of subjects enrolled per country |
|||
Country: Number of subjects enrolled |
Germany: 24
|
||
Worldwide total number of subjects |
24
|
||
EEA total number of subjects |
24
|
||
Number of subjects enrolled per age group |
|||
In utero |
0
|
||
Preterm newborn - gestational age < 37 wk |
0
|
||
Newborns (0-27 days) |
6
|
||
Infants and toddlers (28 days-23 months) |
6
|
||
Children (2-11 years) |
12
|
||
Adolescents (12-17 years) |
0
|
||
Adults (18-64 years) |
0
|
||
From 65 to 84 years |
0
|
||
85 years and over |
0
|
|
|||||||
Recruitment
|
|||||||
Recruitment details |
• 12 subjects aged ≥2 and <6 years were studied in Cohort 1. • 6 subjects ≥28 days and <2 years were studied in Cohort 2. • 6 subjects <28 days were studied in the third cohort. All subjects were recruited to a single centre site in Germany. Subjects could be recruited remotely, but needed to visit the site in order to participate. | ||||||
Pre-assignment
|
|||||||
Screening details |
A total of 24 subjects were studied in 3 cohorts (as agreed in the PIP): • 12 subjects aged ≥2 and <6 years were studied in Cohort 1. • 6 subjects ≥28 days and <2 years were studied in Cohort 2. • 6 subjects <28 days were studied in the third cohort. | ||||||
Period 1
|
|||||||
Period 1 title |
Cohort 1
|
||||||
Is this the baseline period? |
Yes | ||||||
Allocation method |
Not applicable
|
||||||
Blinding used |
Not blinded | ||||||
Blinding implementation details |
N/A
|
||||||
Arms
|
|||||||
Arm title
|
Subjects aged 2 - <6 years | ||||||
Arm description |
The study consisted of 3 consecutive parts. Cohort 1 included 12 subjects aged between 2 and <6 years. No safety concerns emerged after review of this cohort, so 6 subjects aged 28 days to <2 years were enrolled (Cohort 2). No safety concerns were raised after a review of accumulated data so 6 neonates aged from birth to <28 days were enrolled (Cohort 3). The decision to continue after each cohort was based on the recommendation of the IDMC. | ||||||
Arm type |
Experimental | ||||||
Investigational medicinal product name |
Infacort
|
||||||
Investigational medicinal product code |
|||||||
Other name |
|||||||
Pharmaceutical forms |
Granules for oral suspension
|
||||||
Routes of administration |
Oral use
|
||||||
Dosage and administration details |
Administration of Infacort® took place approximately 8 hours following the subject’s prior hydrocortisone dose. The subject had to fast for at least 2 hours (45 minutes for children below 1 year of age) before the dose and were asked not to eat until after the sampling at 60 minutes (30 minutes below 1 year of age). Details of meals (e.g. time of eating and content of meal) were recorded in the CRF.
The Infacort® capsule was opened and the entire contents (i.e. drug granules) were administered either:
1. Directly onto the top, and towards the back of the child’s tongue, by the study nurse/Investigator and washed down immediately with fluid (water, breast milk, formula milk, juice).
2. Indirectly onto the top, and towards the back of the child’s tongue, by the study nurse/Investigator using a spoon and washed down immediately with fluid (water, breast milk, formula milk, juice).
The time, dose, and any other details were recorded in the CRF.
|
||||||
|
|||||||
Notes [1] - The number of subjects reported to be in the baseline period are not the same as the worldwide number enrolled in the trial. It is expected that these numbers will be the same. Justification: The study consisted of three consecutive cohorts. Cohort 1 included 12 subjects aged between 2 and < 6 years. As no safety concerns emerged, 6 subjects aged 28 days to <2 years were enrolled (Cohort 2). A review of accumulated data was then undertaken and again, no safety concerns emerged, so 6 neonates aged from birth to <28 days were enrolled (Cohort 3). The decision to continue after each cohort was based on the recommendation of an Independent Data Monitoring Committee. |
|||||||
Period 2
|
|||||||
Period 2 title |
Cohort 2
|
||||||
Is this the baseline period? |
No | ||||||
Allocation method |
Not applicable
|
||||||
Blinding used |
Not blinded | ||||||
Blinding implementation details |
N/A
|
||||||
Arms
|
|||||||
Arm title
|
Subjects aged 28 days to <2 years | ||||||
Arm description |
- | ||||||
Arm type |
Experimental | ||||||
Investigational medicinal product name |
Infacort
|
||||||
Investigational medicinal product code |
|||||||
Other name |
|||||||
Pharmaceutical forms |
Granules for oral suspension
|
||||||
Routes of administration |
Oral use
|
||||||
Dosage and administration details |
Administration of Infacort® took place approximately 8 hours following the subject’s prior hydrocortisone dose. The subject had to fast for at least 2 hours (45 minutes for children below 1 year of age) before the dose and were asked not to eat until after the sampling at 60 minutes (30 minutes below 1 year of age). Details of meals (e.g. time of eating and content of meal) were recorded in the CRF.
The Infacort® capsule was opened and the entire contents (i.e. drug granules) were administered either:
1. Directly onto the top, and towards the back of the child’s tongue, by the study nurse/Investigator and washed down immediately with fluid (water, breast milk, formula milk, juice).
2. Indirectly onto the top, and towards the back of the child’s tongue, by the study nurse/Investigator using a spoon and washed down immediately with fluid (water, breast milk, formula milk, juice).
The time, dose, and any other details were recorded in the CRF.
|
||||||
|
|||||||
Notes [2] - The number of subjects starting the period is not consistent with the number completing the preceding period. It is expected the number of subjects starting the subsequent period will be the same as the number completing the preceding period. Justification: The study consisted of three consecutive cohorts. Cohort 1 included 12 subjects aged between 2 and < 6 years. As no safety concerns emerged, 6 subjects aged 28 days to <2 years were enrolled (Cohort 2). A review of accumulated data was then undertaken and again, no safety concerns emerged, so 6 neonates aged from birth to <28 days were enrolled (Cohort 3). The decision to continue after each cohort was based on the recommendation of an Independent Data Monitoring Committee. |
|||||||
Period 3
|
|||||||
Period 3 title |
Cohort 3
|
||||||
Is this the baseline period? |
No | ||||||
Allocation method |
Not applicable
|
||||||
Blinding used |
Not blinded | ||||||
Blinding implementation details |
N/A
|
||||||
Arms
|
|||||||
Arm title
|
Subjects aged <28 days | ||||||
Arm description |
- | ||||||
Arm type |
Experimental | ||||||
Investigational medicinal product name |
Infacort
|
||||||
Investigational medicinal product code |
|||||||
Other name |
|||||||
Pharmaceutical forms |
Granules for oral suspension
|
||||||
Routes of administration |
Oral use
|
||||||
Dosage and administration details |
Administration of Infacort® took place approximately 8 hours following the subject’s prior hydrocortisone dose. The subject had to fast for at least 2 hours (45 minutes for children below 1 year of age) before the dose and were asked not to eat until after the sampling at 60 minutes (30 minutes below 1 year of age). Details of meals (e.g. time of eating and content of meal) were recorded in the CRF.
The Infacort® capsule was opened and the entire contents (i.e. drug granules) were administered either:
1. Directly onto the top, and towards the back of the child’s tongue, by the study nurse/Investigator and washed down immediately with fluid (water, breast milk, formula milk, juice).
2. Indirectly onto the top, and towards the back of the child’s tongue, by the study nurse/Investigator using a spoon and washed down immediately with fluid (water, breast milk, formula milk, juice).
The time, dose, and any other details were recorded in the CRF.
|
||||||
|
|
||||||||||||||||||||||||||||
Baseline characteristics reporting groups
|
||||||||||||||||||||||||||||
Reporting group title |
Subjects aged 2 - <6 years
|
|||||||||||||||||||||||||||
Reporting group description |
The study consisted of 3 consecutive parts. Cohort 1 included 12 subjects aged between 2 and <6 years. No safety concerns emerged after review of this cohort, so 6 subjects aged 28 days to <2 years were enrolled (Cohort 2). No safety concerns were raised after a review of accumulated data so 6 neonates aged from birth to <28 days were enrolled (Cohort 3). The decision to continue after each cohort was based on the recommendation of the IDMC. | |||||||||||||||||||||||||||
|
|
|||
End points reporting groups
|
|||
Reporting group title |
Subjects aged 2 - <6 years
|
||
Reporting group description |
The study consisted of 3 consecutive parts. Cohort 1 included 12 subjects aged between 2 and <6 years. No safety concerns emerged after review of this cohort, so 6 subjects aged 28 days to <2 years were enrolled (Cohort 2). No safety concerns were raised after a review of accumulated data so 6 neonates aged from birth to <28 days were enrolled (Cohort 3). The decision to continue after each cohort was based on the recommendation of the IDMC. | ||
Reporting group title |
Subjects aged 28 days to <2 years
|
||
Reporting group description |
- | ||
Reporting group title |
Subjects aged <28 days
|
||
Reporting group description |
- |
|
|||||||||||||||||
End point title |
Maximum levels of serum cortisol concentration up to 240 minutes after intake of study drug as determined by the central laboratory. | ||||||||||||||||
End point description |
The objective of this endpoint is to demonstrate significant absorption of hydrocortisone from the Infacort preparation.
|
||||||||||||||||
End point type |
Primary
|
||||||||||||||||
End point timeframe |
Up to 240 minutes post-administration with Infacort
|
||||||||||||||||
|
|||||||||||||||||
Statistical analysis title |
Primary efficacy analysis | ||||||||||||||||
Statistical analysis description |
At the maximum cortisol level (i.e. at Cmax) a statistically significant increase was seen in cortisol levels compared to baseline for all cohorts combined (p<0.0001). Thus the primary endpoint of the study was met. A statistically significant difference compared to baseline was seen in Cohort 1 (p=0.0005), but for Cohorts 2 and 3, although all subjects showed an increase in cortisol, the difference from baseline was not statistically significant (p=0.0313 at the 1% level).
|
||||||||||||||||
Comparison groups |
Subjects aged 28 days to <2 years v Subjects aged <28 days v Subjects aged 2 - <6 years
|
||||||||||||||||
Number of subjects included in analysis |
24
|
||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||
Analysis type |
equivalence | ||||||||||||||||
P-value |
< 0.0001 | ||||||||||||||||
Method |
Sign test | ||||||||||||||||
Confidence interval |
|
|||||||||||||||||
End point title |
Serum cortisol concentration up to 6 hours after intake of study drug as determined by the central laboratory | ||||||||||||||||
End point description |
|||||||||||||||||
End point type |
Secondary
|
||||||||||||||||
End point timeframe |
Up to 6 hours post-administration of Infacort
|
||||||||||||||||
|
|||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||
Adverse events information
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||
Timeframe for reporting adverse events |
Adverse Events (AEs) were recorded from the time of first intake of Infacort® until Visit 4.
|
||||||||||||||||||||||||||||||||||||||||||||||||||||
Assessment type |
Systematic | ||||||||||||||||||||||||||||||||||||||||||||||||||||
Dictionary used for adverse event reporting
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||
Dictionary name |
MedDRA | ||||||||||||||||||||||||||||||||||||||||||||||||||||
Dictionary version |
18.1
|
||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting groups
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
All subjects
|
||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
All 24 subjects were included within the AE reporting group for the study (Also referred to as the "safety population") | ||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||
Frequency threshold for reporting non-serious adverse events: 5% | |||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
|||
Substantial protocol amendments (globally) |
|||
Were there any global substantial amendments to the protocol? Yes | |||
Date |
Amendment |
||
06 Aug 2015 |
The protocol was amended to allow the following changes:
• Collection of full date of birth.
Changes in important parameters that affect disposition of molecules such as hydrocortisone are age-related. These parameters most importantly include absorption, volume of distribution & clearance. As an example, paracetomol (acetaminophen) clearance (L/hr) increases from 2.02 L/hr at 1 month of age to 4.09 L/hr at 1 year of age and to 14.27 L/hr at 16 years of age (Krasniak et al., 2014). Therefore, collection of year of birth only in subjects is insufficient to enable accurate interpretation of results. Section 13 of the Parent Information Sheet has been amended accordingly.
Originally, the protocol allowed for full date of birth in Section 8.4 but was inconsistent with respect to Section 15.8. The informed consent form however did not allow for collection of the full date of birth.
• Change to the method of Investigational Medicinal Product (IMP) administration.
In Cohort 1 the Investigator administered the IMP in accordance with parent/carer preference and usual clinical practice. The amended protocol now reflects the actual methods of IMP administration adopted during Cohort 1.
• Change to the storage temperature of serum blood samples.
The change to the storage temperature of serum blood samples is necessary to reflect freezer availability in the study site sample processing facility.
• Provision for direct blood sampling if cannulation is not considered suitable by the Investigator.
In the younger subjects (Cohorts 2 & 3) it might not be appropriate to insert a cannula due to the small size of the subject’s veins. In this event a small needle will be used for direct venous blood sampling. This will result in a maximum of 2 venous punctures at each timepoint.
|
||
Interruptions (globally) |
|||
Were there any global interruptions to the trial? No | |||
Limitations and caveats |
|||
Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data. | |||
None. |